No­var­tis CEO Vas Narasimhan's R&D up­date spot­lights next wave of drug stars as well as late-stage fa­vorites

As one of the biggest spenders in bio­phar­ma R&D, No­var­tis ex­ecs love to tout the scope of its late-stage pipeline, spot­light­ing the win­ners most like­ly to cre­ate block­buster rev­enue streams in the near fu­ture.

Build­ing on the 5 drug ap­provals the phar­ma gi­ant ex­pects to end the year with, No­var­tis CEO Vas Narasimhan — who’s done a slate of ac­qui­si­tions topped by the re­cent $9.7 bil­lion Med­Co buy­out — tapped the top emerg­ing drugs as:

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER